/
We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid a…
The business is unprofitable at the operating level (-21.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 19.7% YoY with margins expanding 3.4pp.
Negative free cash flow of -$14M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$68M
▲ +19.7% YoY
Net Income (TTM)
-$20M
▼ -32.0% YoY
Op. Margin
-20.65%
▲ +3.4pp YoY
ROIC
-24.94%
▼ -1.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$14M
▼ -3.4% YoY
Op. Cash Flow (TTM)
-$13M
▼ -2.6% YoY
Net Debt
$6M
Cash & Equiv.
$22M
5Y CAGR: +9.7%
Continue Research